Trial Profile

A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20089 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HS-20089 (Primary)
Indications Advanced breast cancer; Endometrial cancer; Male breast cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Shanghai Hansoh Biomedical

01 Apr 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2026.
01 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
24 Oct 2023 Results (As of Apr. 11th, 2023, n=44) assessing the dose-limiting toxicity (DLT), safety, tolerability, pharmacokinetics, and efficacy of HS-20089 in patients (pts) with advanced solid tumors refractory to standard therapy presented at the 48th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com